BIOMAT Database Logo BIOMAT Database Logo

Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. 2017

Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Comprehensive Epilepsy Center, Dept. of Neurology, Yale University, New Haven, CT, USA; William Beaumont School of Medicine, Oakland University, Rochester, MI, USA. Electronic address: baibing.chen@yale.edu.

Psychiatric and behavioral side effects (PBSEs) are common, undesirable effects associated with antiepileptic drug (AED) use. The objective of the study was to compare the PBSE profiles of older and newer AEDs in a large specialty practice-based sample of patients diagnosed with epilepsy. As part of the Columbia and Yale AED Database Project, we reviewed patient records including demographics, medical history, AED use, and side effects for 4085 adult patients (age: 18 years) newly started on an AED regimen. Psychiatric and behavioral side effects were determined by patient or physician report in the medical record, which included depressive mood, psychosis, anxiety, suicidal thoughts, irritability, aggression, and tantrum. Significant non-AED predictors of PBSE rate were first determined from 83 variables using logistic regression. Predictors were then controlled for in the comparison analysis of the rate of PBSEs and intolerable PBSEs (PBSEs that led to dosage reduction or discontinuation) between 18 AEDs. Psychiatric and behavioral side effects occurred in 17.2% of patients and led to intolerability in 13.8% of patients. History of psychiatric condition(s), secondary generalized seizures, absence seizures, and intractable epilepsy were associated with increased incidence of PBSE. Levetiracetam (LEV) had the greatest PBSE rate (22.1%). This was statistically significant when compared with the aggregate of the other AEDs (P<0.001, OR=6.87). Levetiracetam was also significantly (P<0.001) associated with higher intolerability rate (17.7%), dose decreased rate (9.4%), and complete cessation rate (8.3%), when compared with the aggregate of the other AEDs. Zonisamide (ZNS) was also significantly associated with a higher rate of PBSE (9.7%) and IPBSE (7.9%, all P<0.001). On the other hand, carbamazepine (CBZ), clobazam (CLB), gabapentin (GBP), lamotrigine (LTG), oxcarbazepine (OXC), phenytoin (PHT), and valproate (VPA) were significantly associated with a decreased PBSE rates (P<0.001). Carbamazepine, GBP, LTG, PHT, and VPA were also associated with lower IPBSE rates when compared individually with the aggregate of other AEDs. All other AEDs were found to have intermediate rates that were not either increased or decreased compared with other AEDs. When each AED was compared to LTG, only CBZ had a significantly lower PBSE rate. The main limitations of this study were that the study design was retrospective and not blinded, and the AEDs were not randomly assigned to patients. Psychiatric and behavioral side effects occur more frequently in patients taking LEV and ZNS than any other AED and led to higher rates of intolerability. Lower PBSE rates were seen in patients taking CBZ, CLB, GBP, LTG, OXC, PHT, and VPA. Our findings may help facilitate the AED selection process.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D004832 Epilepsy, Absence A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736) Akinetic Petit Mal,Epilepsy, Minor,Petit Mal Epilepsy,Pyknolepsy,Absence Seizure Disorder,Childhood Absence Epilepsy,Epilepsy Juvenile Absence,Epilepsy, Absence, Atypical,Epilepsy, Petit Mal,Juvenile Absence Epilepsy,Pykno-Epilepsy,Seizure Disorder, Absence,Absence Epilepsy,Absence Epilepsy, Childhood,Absence Epilepsy, Juvenile,Absence Seizure Disorders,Epilepsy, Childhood Absence,Epilepsy, Juvenile Absence,Minor Epilepsy,Petit Mal, Akinetic,Pykno Epilepsy,Pyknolepsies,Seizure Disorders, Absence
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069279 Drug Resistant Epilepsy Epileptic condition in which adequate trials of two tolerated and appropriately chosen and used ANTIEPILEPTIC DRUGS schedules to achieve sustained seizure freedom failed. Drug Refractory Epilepsy,Epilepsy, Drug Refractory,Epilepsy, Drug Resistant,Epilepsy, Intractable,Intractable Epilepsy,Medication Resistant Epilepsy,Refractory Epilepsy,Drug Refractory Epilepsies,Drug Resistant Epilepsies,Epilepsies, Drug Refractory,Epilepsies, Drug Resistant,Epilepsies, Intractable,Epilepsies, Medication Resistant,Epilepsies, Refractory,Epilepsy, Medication Resistant,Epilepsy, Refractory,Intractable Epilepsies,Medication Resistant Epilepsies,Refractory Epilepsies,Refractory Epilepsies, Drug,Refractory Epilepsy, Drug,Resistant Epilepsies, Drug,Resistant Epilepsies, Medication,Resistant Epilepsy, Drug,Resistant Epilepsy, Medication
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy.
February 2007, Epilepsy & behavior : E&B,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Behavioral adverse effects of antiepileptic drugs in epilepsy.
June 2012, Journal of clinical psychopharmacology,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Psychiatric effects of antiepileptic drugs in adults.
June 2018, Geriatrie et psychologie neuropsychiatrie du vieillissement,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.
June 2017, Epilepsy & behavior : E&B,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy.
June 2017, Brain & development,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Discontinuation of antiepileptic drugs in adults with epilepsy.
April 2021, Australian prescriber,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
The medical treatment of epilepsy: managing side effects of antiepileptic drugs.
April 1979, Pediatric annals,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
[Side-effects of antiepileptic drugs].
December 1971, Deutsche medizinische Wochenschrift (1946),
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
[Side effects of antiepileptic drugs].
January 1984, Neurologia i neurochirurgia polska,
Baibing Chen, and Hyunmi Choi, and Lawrence J Hirsch, and Austen Katz, and Alexander Legge, and Richard Buchsbaum, and Kamil Detyniecki
Effects of antiepileptic medications on psychiatric and behavioral comorbidities in children and adolescents with epilepsy.
October 2004, Epilepsy & behavior : E&B,
Copied contents to your clipboard!